Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR; Anti-IL-21–liraglutide Study Group investigators and contributors. von Herrath M, et al. Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. Epub 2021 Mar 1. Lancet Diabetes Endocrinol. 2021. PMID: 33662334 Clinical Trial.
Current state of antigen-specific immunotherapy for type 1 diabetes.
Kreiner FF, von Scholten BJ, Coppieters K, von Herrath M. Kreiner FF, et al. Among authors: von scholten bj, von herrath m. Curr Opin Endocrinol Diabetes Obes. 2021 Aug 1;28(4):411-418. doi: 10.1097/MED.0000000000000647. Curr Opin Endocrinol Diabetes Obes. 2021. PMID: 34101651 Review.
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Dejgaard TF, von Scholten BJ, Christiansen E, Kreiner FF, Bardtrum L, von Herrath M, Mathieu C, Madsbad S; ADJUNCT ONE and ADJUNCT TWO Investigators. Dejgaard TF, et al. Among authors: von scholten bj, von herrath m. Diabetes Obes Metab. 2021 Dec;23(12):2752-2762. doi: 10.1111/dom.14532. Epub 2021 Sep 28. Diabetes Obes Metab. 2021. PMID: 34463425 Free PMC article. Clinical Trial.
Trials in type 1 diabetes: Antigen-specific therapies.
Coppieters KT, Harrison LC, von Herrath MG. Coppieters KT, et al. Clin Immunol. 2013 Dec;149(3):345-55. doi: 10.1016/j.clim.2013.02.002. Epub 2013 Feb 15. Clin Immunol. 2013. PMID: 23490422 Free PMC article. Review.
Non-antigenic and antigenic interventions in type 1 diabetes.
Rydén AK, Wesley JD, Coppieters KT, Von Herrath MG. Rydén AK, et al. Hum Vaccin Immunother. 2014;10(4):838-46. doi: 10.4161/hv.26890. Epub 2013 Oct 28. Hum Vaccin Immunother. 2014. PMID: 24165565 Free PMC article. Review.
Current and future therapies for type 1 diabetes.
von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M. von Scholten BJ, et al. Among authors: von herrath m. Diabetologia. 2021 May;64(5):1037-1048. doi: 10.1007/s00125-021-05398-3. Epub 2021 Feb 17. Diabetologia. 2021. PMID: 33595677 Free PMC article. Review.
337 results